Jamie Chaft, MD

Videos

The Case for Immunotherapy Alone for Patients With PD-L1-High NSCLC in the First-Line Setting

09/29/2023

At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.

At the Great Debates & Updates...

09/29/2023

Oncology

Videos

The Case for Neoadjuvant Immunotherapy in Resectable NSCLC

10/05/2023

Jamie Chaft , MD;

At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

At the Great Debates & Updates...

10/05/2023

Oncology

Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center

Videos

Updated 5-Year Data From the IMpower010 Trial

09/17/2024

Jamie Chaft , MD;

Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage...

Jamie Chaft, MD, discusses the...

09/17/2024

Oncology